drug
foralumab
Phase 2updated 6mo agoby $TLSA Tiziana Life Sciences Ltd
Phase 2community read0 votes
indications
indications
Alzheimer's Disease
all catalysts(0)
nothing on the calendar yet
Trials studying foralumab
- phase2A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
- phase2The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
- phase2Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
- phase2A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
- —Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
- phase2Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
- phase1Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
News(4)
- Tiziana touts multiple sclerosis win at lower dose as high dose misses markIn a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after t…biospace · 14d ago
- Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose strugglesTiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose mis…fiercebiotech · 15d ago
- Tiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerBOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with i…globenewswire_health · 3mo ago
- Tiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerBOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with i…globenewswire_health · 3mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that